Navigation Links
Hebrew University research leads to advanced trials of new cancer treatment
Date:6/15/2009

Jerusalem, June 14, 2009 Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells.

The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year's Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting.

Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.

Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases.

The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods.

Prof. Hochberg's research was patented by Yissum Research Development Company of the Hebrew University. In 2005 Yissum established BioCancell Inc., to which it licensed the technology. The company is now traded in the Tel Aviv stock exchange (TASE). BioCancell's leading product, BC-819, has demonstrated efficacy in clinical trials (now in an advanced stage) in Israel and the US for the treatment of human bladder, pancreatic and ovarian cancers.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related medicine news :

1. Safe Playground to be Built at Politz Hebrew Academy
2. Groundbreaking for Safe Playground Build at Politz Hebrew Academy
3. Hebrew University scientist develop technique for eliminating reblockage of arteries
4. Hebrew University scientists succeed through stem cell therapy in reversing brain birth defects
5. Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem
6. The Connecticut Hospice, Inc. Announces the Arrival of Six Nurse Scholars From The Henrietta Szold-Hadassah-Hebrew University School of Nursing
7. RNA engineering to combat series of illnesses wins Kaye Award for Hebrew University dean
8. Hebrew University research on octopuses sheds light on memory
9. Humans have more distinctive hearing than animals, Hebrew U study shows
10. Robert H. Smith Feeding the Future with $15 Million Gift to Hebrew University of Jerusalem
11. Hebrew SeniorLife researcher finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University research leads to advanced trials of new cancer treatment
(Date:1/23/2017)... ... , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of ... making new water infrastructure a number one priority. “As we usher in a new ... to become a top priority of our new political change agents.” Kleyne pointed out ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... and production applications. However, choosing the right method is paramount to success. Selecting ... more often in situations where multiple persons use the same equipment. Rare or ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities ... These resources have been developed for use by nutrition educators and influencers ...
(Date:1/22/2017)... SAINT- MALO, FRANCE (PRWEB) , ... January 22, 2017 , ... ... the Indian Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. ... Africa, Phytocéane used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Ahead of today,s trading session, Stock-Callers.com ... have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ). ... laggards on Friday, January 20 th , 2017, down on the ... on these stocks now at: ...
(Date:1/23/2017)...  ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B ... qu,ils se sont mis d,accord sur le règlement mondial ... et 3B seront autorisés à vendre leurs produits existants ... ResMed effectuera le paiement de la décision en une ... Floride entre les deux parties. Le règlement n,inclut pas ...
(Date:1/23/2017)... , Jan. 23, 2017 Just two weeks remain until legal ... property, gather in Central London to discuss the ... kind in the market, Parallel Trade 2017 . In ... list of attendees which is available to read in the event ... Some ...
Breaking Medicine Technology: